Air Deccan, India's first low-cost carrier operating in the domestic sector, Friday announced the release of 3,300 tickets priced at Rs.1 (about two cents) for reservations in September and October.

The airline also started the booking for over 6,500 tickets priced at Rs.500 ($11.35), excluding taxes, for the two months.

The reservations are open for the Airbus sectors that include Delhi-Bangalore-Delhi, Delhi-Mumbai-Delhi, Delhi-Guwahati-Delhi, Delhi-Chennai-Delhi, Delhi-Hyderabad-Delhi, Chennai-Kolkata-Chennai, and Mumbai-Chennai-Mumbai.

Air Deccan low fare tickets can be booked through the company Web site, authorised travel agents, airport counters and 24-hour call centres.

The budget airline operates 115 flights a day, with a fleet size of five Airbus A-320s and 12 ATR 42s. It has placed order for 62 brand new aircrafts -- 32 Airbus A-320s and 30 ATR-72-500s.

The new aircraft will be delivered over the next five years and take up Air Deccan's flights close to 600 per day.

*_*

Cadila to supply free medicines for flood relief

Cadila Healthcare Ltd, one of India's leading pharmaceutical companies, said Friday the company would supply medicines free of cost to the flood-affected in the country.

The company said in the aftermath of the floods, the threat of infectious diseases such as gastroenteritis, malaria, viral fever, respiratory tract infections, typhoid and skin infections loom large.

A special control room has been set up at Cadila's corporate office in Ahmedabad for supply of medicines, said a statement issued to the Bombay Stock Exchange.

Apart from medicines to combat various infectious diseases, the control room will also provide ancillary items such as IV fluids, disposable syringes and disposable needles.

*_*

USFDA clears Lupin's Goa drugs facility

Pharmaceutical major Lupin Ltd said Friday that the company's oral dosage facility located in Goa has successfully cleared the inspection by the US Foods and Drugs Administrator (USFDA).

The facility, commissioned in March 2004, was set up to enable company's foray in "non-cephalosporin" oral dosage forms for advanced markets, said a statement issued to the Bombay Stock Exchange.

"This event re-affirms Lupin's focus in participating in the US and other advanced markets," Kamal Sharma, managing director of Lupin.

"The approval will enable Lupin to significantly enhance its product offering in the US, European Union and other advanced markets," he said, adding the facility in Goa is Lupin's 11th plant to receive USFDA approval.

Earlier, the company's plant at Tarapur, Maharashtra, had also received USFDA approval.

*_*

Apollo Hospitals raises $65 million through GDRs

Apollo Hospitals Enterprise Ltd, a healthcare services chain, said Friday that the company has successfully raised $65.1 million through the issue of 8.35 million global depositary receipts (GDRs).

Each GDR represents one underlying share and will be listed on the Luxembourg Stock Exchange, said a statement issued to the Bombay Stock Exchange.

The GDRs were placed through a book building exercise. Citigroup and Kotak acted as book runners and joint lead managers on this transaction. The issue generated demand of about four times from investors across the US, Asia and Europe.

"The response to the offering underscored investor interest in the strong growth story of the company," said Prathap C. Reddy, chairman of Apollo Hospitals Enterprise.

"The proceeds of the issue will be used for expansion activities, working capital and general corporate purposes," he added.